Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2...

Teplizumab delays progression from stage 2 to stage 3 type 1 diabetes (T1D). Epstein-Barr virus (EBV) reactivation after teplizumab is usually transient and mild. We report EBV reactivation-associated secondary hemophagocytic lymphohistiocytosis (HLH) in an adult with trisomy 21 who was treated with teplizumab.

We describe the clinical course, virologic testing, histopathology, treatment, and follow-up of a 44-year-old man with trisomy 21 and stage 2 T1D after a 14-day teplizumab course.

Six days after completion of the 14-day teplizumab course, he developed respiratory, hepatic, and renal failure. EBV PCR peaked at >2,000,000 copies/mL; serology confirmed reactivation. Lymph node biopsy showed EBV-associated lymphoproliferation, and criteria for secondary HLH were fulfilled (HScore 238). Dexamethasone and four weekly rituximab doses were associated with clinical, biochemical, and virologic recovery. At 12 months, he remained clinically stable with stage 2 T1D and no insulin treatment.

This case documents EBV reactivation-associated secondary HLH after teplizumab treatment in a patient with trisomy 21. Causality cannot be established, and the absence of pretreatment EBV PCR limits assessment of whether preexisting EBV DNAemia at treatment initiation contributed to the poor outcome. The observation raises a plausible but unproven host-virus-drug interaction and supports early EBV PCR and HLH evaluation after severe inflammatory deterioration after teplizumab.